Automated Quantitative Assessment of HER-2/neu Immunohistochemical Expression in Breast Cancer
暂无分享,去创建一个
Kyle J. Myers | Marios A. Gavrielides | Hela Masmoudi | Nicholas Petrick | Stephen M. Hewitt | N. Petrick | K. Myers | S. Hewitt | M. Gavrielides | Héla Masmoudi
[1] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.
[2] Hiroko Yamashita,et al. Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer , 2003, Breast Cancer Research.
[3] Greg Yothers,et al. Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience. , 2002, Journal of the National Cancer Institute.
[4] K A Matkowskyj,et al. Quantitative Immunohistochemistry by Measuring Cumulative Signal Strength Using Commercially Available Software Photoshop and Matlab , 2000, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[5] S J Schnitt,et al. Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] R. Gelber,et al. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] John R. Mackey,et al. Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC→T) with Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab (AC→TH) with Docetaxel, Carboplatin and Trastuzumab (TCH) in Her2neu Positive Early Breast Cancer Patients: BCIRG 006 Study. , 2009 .
[8] Min C. Shin,et al. Does colorspace transformation make any difference on skin detection? , 2002, Sixth IEEE Workshop on Applications of Computer Vision, 2002. (WACV 2002). Proceedings..
[9] Anthony Rhodes,et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2007, Archives of pathology & laboratory medicine.
[10] Hung Chiang,et al. Interobserver reproducibility of Her-2/neu protein overexpression in invasive breast carcinoma using the DAKO HercepTest. , 2002, American journal of clinical pathology.
[11] M. Hall,et al. TOR Signaling in Growth and Metabolism , 2006, Cell.
[12] Nandini Dendukuri,et al. Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis , 2007, Canadian Medical Association Journal.
[13] E. Frenkel,et al. Assessment of HER-2/neu status in breast cancer. Automated Cellular Imaging System (ACIS)-assisted quantitation of immunohistochemical assay achieves high accuracy in comparison with fluorescence in situ hybridization assay as the standard. , 2001, American journal of clinical pathology.
[14] Oliver Hoffmann,et al. Prognostic relevance of activated Akt kinase in node-negative breast cancer: a clinicopathological study of 99 cases , 2004, Modern Pathology.
[15] M. Dowsett,et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.
[16] K I Bland,et al. Molecular Biomarkers for Breast Cancer Prognosis: Coexpression of c-erbB-2 and p53 , 2001, Annals of surgery.
[17] D. Rimm,et al. Automated subcellular localization and quantification of protein expression in tissue microarrays , 2002, Nature Medicine.
[18] Stephen M Hewitt,et al. Perspectives in tissue microarrays. , 2004, Combinatorial chemistry & high throughput screening.
[19] K. Shen,et al. Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer , 2008 .
[20] H A Lehr,et al. Quantitative evaluation of HER-2/neu status in breast cancer by fluorescence in situ hybridization and by immunohistochemistry with image analysis. , 2001, American journal of clinical pathology.
[21] Pierre Soille,et al. Morphological Image Analysis: Principles and Applications , 2003 .
[22] C. Hudis,et al. Cardiac dysfunction in the trastuzumab clinical trials experience. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] Larry Norton,et al. HER2 and response to paclitaxel in node-positive breast cancer. , 2007, The New England journal of medicine.
[24] D. Rimm,et al. Immunohistochemistry and quantitative analysis of protein expression. , 2009, Archives of pathology & laboratory medicine.
[25] T. Seidal,et al. Interpretation and Quantification of Immunostains , 2001, The American journal of surgical pathology.
[26] Holly Dressman,et al. Towards integrated clinico-genomic models for personalized medicine: combining gene expression signatures and clinical factors in breast cancer outcomes prediction. , 2003, Human molecular genetics.
[27] G. Oberhuber,et al. Is fluorescence in situ hybridization really superior to HercepTest? , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] C Sotiriou,et al. Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[29] David L Rimm,et al. Quantitative analysis of breast cancer tissue microarrays shows that both high and normal levels of HER2 expression are associated with poor outcome. , 2003, Cancer research.
[30] Danila Coradini,et al. Biomolecular prognostic factors in breast cancer , 2004, Current opinion in obstetrics & gynecology.
[31] B. Everitt,et al. Statistical methods for rates and proportions , 1973 .
[32] A. Thor,et al. Histopathologic Characteristics Predicting HER-2/neu Amplification in Breast Cancer , 2007 .
[33] Jinha M. Park,et al. Diagnostic Evaluation of HER-2 as a Molecular Target: An Assessment of Accuracy and Reproducibility of Laboratory Testing in Large, Prospective, Randomized Clinical Trials , 2005, Clinical Cancer Research.
[34] Andrew W. Fitzgibbon,et al. Direct Least Square Fitting of Ellipses , 1999, IEEE Trans. Pattern Anal. Mach. Intell..
[35] R. Gelber,et al. Polychemotherapy for early breast cancer , 2001, The Lancet.
[36] Robert D Cardiff,et al. Activation of Akt-1 (PKB-alpha) can accelerate ErbB-2-mediated mammary tumorigenesis but suppresses tumor invasion. , 2004, Cancer research.
[37] I Vergote,et al. A scoring system for immunohistochemical staining: consensus report of the task force for basic research of the EORTC-GCCG. European Organization for Research and Treatment of Cancer-Gynaecological Cancer Cooperative Group. , 1997, Journal of clinical pathology.
[38] O. Kallioniemi,et al. Immunohistochemical determination of estrogen and progesterone receptors in human breast carcinoma. Correlation with histopathology and dna flow cytometry , 1990, Cancer.
[39] Stephen M Hewitt,et al. Tissue microarrays: bridging the gap between research and the clinic , 2005, Expert review of proteomics.
[40] Anne Kallioniemi,et al. Molecular signatures of breast cancer--predicting the future. , 2002, The New England journal of medicine.
[41] H. Kundel,et al. Measurement of observer agreement. , 2003, Radiology.
[42] J. Fletcher,et al. HER-2/neu (c-erb-B2) gene and protein in breast cancer. , 1999, American journal of clinical pathology.
[43] Hubert Cardot,et al. Cooperation of color pixel classification schemes and color watershed: a study for microscopic images , 2002, IEEE Trans. Image Process..
[44] Lajos Pusztai,et al. Breast cancer biomarkers and molecular medicine , 2003, Expert review of molecular diagnostics.
[45] S. Bose,et al. The Akt pathway in human breast cancer: a tissue-array-based analysis , 2006, Modern Pathology.
[46] Andrew S. Glassner,et al. Principles of Digital Image Synthesis , 1995 .
[47] Ioannis Pitas,et al. Automated evaluation of her-2/neu status in breast tissue from fluorescent in situ hybridization images , 2005, IEEE Transactions on Image Processing.
[48] O. Stål,et al. Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients , 2002, British Journal of Cancer.
[49] Greg Yothers,et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.
[50] Greg Yothers,et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] J. Bartlett,et al. The clinical evaluation of HER‐2 status: which test to use? , 2003, The Journal of pathology.
[52] S. Edge,et al. Prognostic factors in breast cancer , 2005 .
[53] S Toikkanen,et al. Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[54] John J Spinelli,et al. HER-2/neu in Breast Cancer: Interobserver Variability and Performance of Immunohistochemistry with 4 Antibodies Compared with Fluorescent In Situ Hybridization , 2001, Modern Pathology.
[55] Hubert Cardot,et al. Bayesian marker extraction for color watershed in segmenting microscopic images , 2002, Object recognition supported by user interaction for service robots.
[56] Cornelius Diamond,et al. A multimarker model to predict outcome in tamoxifen-treated breast cancer patients. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.
[57] Lajos Pusztai,et al. Breast cancer biomarkers and molecular medicine: part II , 2004, Expert review of molecular diagnostics.
[58] C R King,et al. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[59] R. F. Wagner,et al. Assessment of medical imaging systems and computer aids: a tutorial review. , 2007, Academic radiology.
[60] A. Gown,et al. Accuracy and precision in HER2/neu testing in breast cancer: are we there yet? , 2004, Human pathology.
[61] K. Edmiston,et al. HER-2 Status in Breast Cancer: Correlation of Gene Amplification by FISH With Immunohistochemistry Expression Using Advanced Cellular Imaging System , 2006, Applied immunohistochemistry & molecular morphology : AIMM.
[62] H. Tsuda,et al. Quantitative immunohistochemical evaluation of HER2/neu expression with HercepTestTM in breast carcinoma by image analysis , 2001, Pathology international.
[63] Abdesselam Bouzerdoum,et al. Skin segmentation using color pixel classification: analysis and comparison , 2005, IEEE Transactions on Pattern Analysis and Machine Intelligence.